| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Olgotrelvir | STI-1558; STI1558 | Approved | Texas A&M University | Ovydso, 奥维宁 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Zhejiang Acea Pharmaceutical Co Ltd | 2025-10-28 | Coronavirus Disease 2019 (COVID-19); Pulmonary Disease, Chronic Obstructive | Details |